GLP-1 Receptor Agonists: The Emerging Case for Microdosing
Key Takeaways:
- A narrative review in Cureus finds that the benefits of GLP-1 receptor agonists (GLP-1RAs) extend beyond weight reduction to cardiovascular, renal, metabolic and other outcomes.
- Its authors propose microdosing – smaller, fractional doses – as a tolerability-first approach for people who respond strongly to standard doses or who struggle with gastrointestinal side effects.
- Direct evidence is extremely limited, and microdosing remains off-label, so the authors advise caution and clinician guidance.
Why a tolerability-first conversation is gaining ground
In a recent non-systematic narrative review published in the journal Cureus, researchers summarised the current evidence on the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and discussed the possible benefits of microdosing these agents. Their central question is a practical one that clinicians increasingly face in consultation rooms: if the multisystem benefits of this drug class are real, can smaller doses preserve enough of them to keep people in treatment?
Obesity remains a substantial health concern
Obesity continues to represent a significant health concern worldwide. In the United States (US), the prevalence of generalised obesity among adults, defined as a body mass index (BMI) above 30 kg/m², and of extreme obesity, defined as a BMI above 40 kg/m², has been increasing. Childhood obesity, by contrast, is defined using age- and sex-specific BMI thresholds rather than a single fixed cut-off.
Data from a survey conducted between 2021 and 2023 indicate that 21% of children and adolescents and 40% of adults in the US were living with obesity. Those figures give a sense of the scale of the population for whom pharmacological options are now being considered, and of the pressure placed on services that support people with obesity and related conditions.
From exenatide to semaglutide: a rapidly expanding drug class
The development of GLP-1RAs has been a remarkable advancement in the treatment of obesity and diabetes. Exenatide was the first GLP-1RA approved for type 2 diabetes in 2005, and the class has since expanded to include liraglutide, dulaglutide and semaglutide.
Success, however, has brought its own difficulties. Demand for GLP-1RAs far exceeds supply, and this imbalance has contributed to high costs and significant gaps in care. The authors suggest that these pressures have encouraged greater use of medication microdosing, as people and their clinicians look for ways to stretch limited or expensive supplies of medication further.
What microdosing means in this context
The term microdosing has a specific technical origin. It originally referred to sub-pharmacologically active doses used in drug-development studies, where the intention was never therapeutic effect. The review deliberately uses the term in a different, clinical sense: smaller, fractional doses of a medication that may allow people to receive some therapeutic benefit while extending their use of the medication.
That distinction matters when interpreting the literature, because the pharmacokinetic and the clinical uses of the word describe quite different practices. It is the second, clinical meaning that the review sets out to examine.
Clinical benefits of GLP-1 receptor agonists
GLP-1RAs modulate energy intake and promote satiety through agonism of the GLP-1 receptor. They also improve glycaemic control by suppressing glucagon and stimulating insulin secretion. These two mechanisms account for much of the drug class’s original appeal in both diabetes and obesity care.
A recent umbrella review noted trends towards improvements in respiratory, renal, metabolic, endocrine and cardiovascular outcomes, as well as cognitive function, with GLP-1RAs. Taken together, these findings suggest that the benefits of the drug class may extend beyond weight reduction across multiple organ systems, which is precisely why the question of preserving those benefits at lower doses has become interesting.
Cardiovascular and renal outcomes
A meta-analysis reported that GLP-1RAs led to significant reductions in major adverse cardiovascular events (MACE) and mortality. A further meta-analysis showed that long-acting GLP-1RAs reduced MACE and improved a composite kidney outcome among people with type 2 diabetes.
An umbrella review similarly reported that GLP-1RAs were associated with improvements in body weight, glycaemic control and various renal and cardiovascular outcomes. Importantly, the certainty of evidence was lower for some of the cardiovascular and kidney outcomes, so these associations should not all be read with equal confidence.
Emerging and early-stage evidence
Beyond the established indications, the review points to areas where evidence is still at a very early stage. A case report described a 34-year-old woman with type 2, stage III lipoedema who showed improvements after 30 days of treatment with low-dose tirzepatide, a dual GIP and GLP-1 receptor agonist. A single case, however, cannot establish treatment efficacy.
A systematic review indicated that GLP-1RAs significantly improved one measure of motor function among people with Parkinson’s disease. Other motor outcomes did not improve significantly, and adverse events were more frequent. This is a useful reminder that a positive signal on one outcome measure does not amount to a demonstrated clinical benefit overall.
Current dosing regimens of GLP-1RAs
Gradual dose titration is recommended for GLP-1RAs such as liraglutide and semaglutide in order to reduce the risk of adverse gastrointestinal (GI) effects.
For obesity, semaglutide is initiated at 0.25 mg once weekly for four weeks, then increased to 0.5 mg, 1 mg and 1.7 mg once weekly for four weeks each, until reaching 2.4 mg after 16 weeks. Liraglutide, by contrast, is initiated at 0.6 mg daily for the first week, then 1.2 mg daily, 1.8 mg daily and 2.4 mg daily for one week each, reaching 3 mg daily after four weeks.
For diabetes treatment, semaglutide and liraglutide can be dosed up to 2 mg and 1.8 mg respectively, as weekly and daily subcutaneous injections. Tirzepatide has identical dosing for both type 2 diabetes and obesity: treatment starts at 2.5 mg once weekly, increases to 5 mg once weekly four weeks later, and then rises in further 2.5 mg increments every four weeks to a maximum of 15 mg weekly.
The logic of these schedules is worth noting. Titration exists because tolerability, rather than efficacy alone, governs how quickly a person can reach a therapeutic dose. Fractional dosing takes that same logic and extends it further down the dose range. Understanding titration, tolerability and shared decision-making in enough depth to have these conversations well is now core to obesity and diabetes practice, and it forms the focus of the College of Contemporary Health’s CPD short course GLP-1RA Therapy: The Complete Programme.
Tolerability and the case for microdosing
The primary limitation of long-term GLP-1RA use is adverse GI effects, including nausea, diarrhoea, constipation and vomiting. These are also among the leading causes of treatment discontinuation, which means that tolerability is not a secondary concern but a direct determinant of whether anyone benefits from treatment at all.
More severe adverse effects, including intestinal obstruction, delayed gastric emptying and biliary disease, have been variably reported, with inconsistent evidence regarding these complications. Notably, tolerability has often been found to improve over time, which suggests that fractional or lower dosing may support treatment continuity.
Microdosing as a tolerability-first framework
The authors propose microdosing as a tolerability-first framework, enabling clinicians to personalise dosing to the individual and potentially reduce barriers to treatment. They suggest it could be a valuable option for people who have exaggerated pharmacological responses to a standard dose, and for those who are highly sensitive to adverse effects.
Two important caveats accompany the proposal. First, studies on the effects of microdosing GLP-1RAs are extremely limited. Second, the established benefits of standard GLP-1RA doses cannot be assumed to persist with fractional dosing. Dose-escalation trials do suggest a strong therapeutic response in some people at submaximal doses, which is part of what makes the idea plausible, but plausibility is not proof.
What the evidence on lower doses currently shows
A prospective observational study found improvements in body weight, BMI, triglycerides, glycated haemoglobin and low-density lipoprotein cholesterol with low-dose tirzepatide among non-diabetic adults with obesity.
In addition, a pooled analysis of phase III trials assessing once-weekly semaglutide doses of 0.5 mg and 1 mg indicated improved tolerability over time and reduced sensitivity to adverse GI events with long-term exposure.
Both findings are encouraging, but the review is clear about their status: these studies provide indirect support rather than direct evidence from trials specifically designed to test a microdosing strategy.
Practical and safety considerations
The review also notes two constraints that clinicians need to weigh before considering this approach. Microdosing is an off-label approach, and fractional dosing using existing injection devices may raise sterility and safety considerations. The authors therefore recommend caution and clinician guidance before anyone begins a microdosing regimen.
Concluding remarks
Collectively, although microdosing emerged as a pharmacokinetic tool in drug development, the authors describe it as an emerging pragmatic approach in clinical practice. Alongside other treatment modalities, it may better support people in reaching their health goals and improve their quality of life.
The honest conclusion, however, is that there is limited direct evidence on microdosing GLP-1RAs. Further research is warranted to confirm whether fractional dosing helps maintain the long-term benefits that have been demonstrated at standard doses. For now, the concept is best understood as a personalised, tolerability-led hypothesis worth studying rather than a settled standard of care.
CCH insight
Conversations about titration, tolerability and dose personalisation are becoming a routine part of obesity and diabetes care, and they demand a confident grasp of both the pharmacology and the person in front of you.
The College of Contemporary Health’s CPD short course GLP-1RA Therapy: The Complete Programme is designed for healthcare professionals who want to build exactly that confidence, covering how these medicines work, how they are dosed and titrated, how adverse effects are anticipated and managed, and how to support people effectively throughout treatment.
